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ABSTRACT: Potato virus X (PVX) is a flexuous plant virus-based
nanotechnology with promise in cancer therapy. As a high aspect
ratio biologic (13 × 515 nm), PVX has excellent spatial control in
structures and functions, offering high-precision nanoengineering
for multivalent display of functional moieties. Herein, we
demonstrate the preparation of the PVX-based nanocarrier for
delivery of tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), a promising protein drug that induces apoptosis in
cancer cells but not healthy cells. TRAIL bound to PVX by
coordination bonds between nickel-coordinated nitrilotriacetic
acid on PVX and His-tag on the protein could mimic the bioactive
“membrane-bound” state in native TRAIL, resulting in an
elongated nanoparticle displaying up 490 therapeutic protein molecules. Our data show that PVX-delivered TRAIL
activates caspase-mediated apoptosis more efficiently compared to soluble TRAIL; also in vivo the therapeutic
nanoparticle outperforms in delaying tumor growth in an athymic nude mouse model bearing human triple-negative
breast cancer xenografts. This proof-of-concept work highlights the potential of filamentous plant virus nanotechnologies,
particularly for targeting protein drug delivery for cancer therapy.
KEYWORDS: plant viral nanoparticle, potato virus X, tumor necrosis factor-related apoptosis-inducing ligand, death receptor,
drug delivery, nanomedicine, anticancer therapy
The ultimate goal toward effective anticancer therapy isto develop therapeutics that specifically elicit apoptosisin cancer cells while sparing non-malignant cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) has been identified as one of the promising
candidate therapeutics. TRAIL is an innate immune cytokine
broadly expressed by activated immune cells responsible for
suppressing tumor initiation and metastasis.1,2 The protein
specifically binds to death receptors, namely DR4 and DR5,
which are overexpressed in many cancer cells but not healthy
cells. TRAIL-DR4/5 interactions launch a signaling cascade
triggering a caspase-dependent apoptosis process.3,4 Similar to
most TNF-ligands, TRAIL is expressed as a homotrimeric type
II transmembrane protein or converted into a soluble form
upon proteolytic cleavage. It should be noted that membrane-
bound TRAIL induces stronger receptor oligomerization and
thus activates apoptosis more efficiently than its soluble
counterpart.5,6 Since its discovery, TRAIL has been widely
developed and tested as a therapeutic protein in oncology with
promising results in various preclinical models.7 However,
clinical trials with soluble TRAIL were rather disappointing:
While TRAIL therapy demonstrated safety, lack of efficacy was
attributed to the fact that soluble TRAIL has poor
physicochemical properties and does not effectively trigger
apoptosis in cancer cells.8−10 Therefore, there is a need for the
rational design and development of delivery platforms to
present multivalent TRAIL in a surface-bound state.
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Advances in nanotechnology and drug delivery have
provided myriad rational designs of nanoparticles (NPs)
varied in sizes, shapes, compositions, or surface chemistries
to meet the need for safe and effective delivery of TRAIL.11−13
Examples of TRAIL delivery systems include liposomes,14
polymer-based,15 protein-based,16 or inorganic NPs.17 In most
of the cases, the therapeutic proteins were chemically
conjugated onto the NP surface via designated cysteine or
N-terminal lysine,18 to display immobilized TRAIL mimicking
the membrane-bound state. As with many drug delivery
approaches, efforts in designing and developing TRAIL
delivery systems have been focused on the use of spherical
NPs, but this may not be optimal. Recently, a growing body of
data from the studies on the shape effects of NPs in
microfluidic models and animal models indicates that a
paradigm shift is needed and that anisotropic nanomaterials
with high aspect ratios (length/width) >5 may be more
suitable for drug delivery.19−21 High aspect ratio, elongated
NPs are less recognized and taken up by phagocytic cells and
have enhanced margination, extravasation, and tissue pene-
tration in comparison to the isotropic counterparts.20
Furthermore, nanorods or filaments exhibit a larger contact
surface area, permitting more efficient display and cross-linking
between functional modules and targeted receptors, as
compared to spherical nanomaterials that may not achieve
multivalent interactions with the target cell/receptor due to
their high curvature.20
While there are considerable designs of spherical nano-
carriers, fewer options are present when it comes to anisotropic
NPs. It remains challenging to precisely control the synthesis
of high aspect ratio materials with excellent monodispersity
using synthetic approaches. Carbon nanotubes (CNTs) and
filomicelles are among a few synthetic materials that have been
prepared and explored as drug delivery carriers.22,23 Nano-
vectorization of TRAIL with single-walled CNTs is the only
example of using high aspect ratio nanostructures; the TRAIL
nanovector exhibited enhanced cell killing effects in vitro.24
Interestingly, conjugated TRAIL, even in its monomeric form,
can also induce clustering of death receptors and efficient
activated apoptosis compared to soluble TRAIL, implying the
advantages of NP-bound TRAIL. While the structures and
functionalization of CNTs are well-controlled, there are still
controversies regarding toxicity, and thus there is a need to
further explore other options for engineering guidelines of rod-
shaped NPs and also to provide suitable materials in clinics.
Here, we turned toward nature’s nanocarriers and are
repurposing the rod-shaped and filamentous plant viruses for
drug delivery applications.25−27 One of the promising
candidates is potato virus X (PVX), a plant virus belonging
to the Potexvirus group. The virion is assembled from 1270
identical 25 kDa coat protein (CP) units orderly arranged
around its single-stranded RNA; the assembled construct
results in a flexuous elongated NP measuring 515 nm in length
and 13 nm in diameter. Via mechanical inoculation and
extraction from Nicotiana benthamiana leaves, ∼20 mg of PVX
is typically obtained from 100 g of infected leaf material; the
biomanufacturing can be scaled up via farming. Being a
biologic nanotechnology, PVX particles are obtained with a
high degree of reproducibility and monodispersity.28 These
characteristics are important factors for quality control and
assurance (QC/QA), especially when entering the translational
pathway. The proteinaceous scaffold from PVX is biocompat-
ible, biodegradable, and non-infectious to mammal cells,
adding a layer of biosafety. PVX was shown to be biosafe
with no apparent effects on human erythrocytes in vitro and
neither toxic nor teratogenic in warm-blooded animals.29
Regarding its engineerability, the viral NP, with multiple
surface-exposed residues such as lysine and cysteine, can be
readily modified to load not only single but multiple modules
such as peptide ligands or epitopes as well as fluorescent
probes and MRI contrast agents.30−32 PVX displaying targeting
ligands is stable in serum and thus is applicable for in vivo
studies.33 Besides bioconjugation to display functional
modules, hydrophobic drugs such as doxorubicin can also be
loaded into grooves of the protein assembly via hydrophobic
interactions.27 In agreement with observations in synthetic
anisotropic systems,20 PVX was demonstrated to have
enhanced tumor homing compared to its spherical viral
counterpart, cowpea mosaic virus.29 Together, the engineer-
ability and structural properties make PVX an intriguing
nanoplatform technology, and it has been investigated for
biomedical applications such as drug delivery,29 bioimag-
ing,30,34 and immunotherapies.31,32
Here, we report the development of the flexuous,
filamentous PVX for presenting and delivering “membrane-
bound” TRAIL. To develop therapeutic TRAIL-loaded PVX,
we utilized noncovalent conjugation based on the coordination
bonds between nickel-coordinated nitrilotriacetic acid (Ni-
NTA) modules displayed on PVX surface and TRAIL with an
N-terminal His-tag (Figure 1). This method offers several
advantages vs traditional bioconjugation strategies: (1) PVX
with multiple surface-exposed lysines can be targeted to display
up to 1000−1500 small chemical modifiers (here Ni-NTA) per
particle;30,35 the conjugation of high molecular weight
molecules such as proteins or enzymes to viral NP systems
generally yields lower conjugation efficiencies.36,37 (2) As most
recombinant proteins expressed from bacterial systems
typically incorporate a His-tag for purification either at the
N- or C-terminus, no post-harvest/purification modification is
required for TRAIL conjugation, thus reducing the manu-
facturing steps, heterogeneity in chemical conjugation, and also
Figure 1. Preparation of the therapeutic conjugate, PVX-
HisTRAIL via the coordination bond between a Ni-NTA group
on PVX (Ni-NTA was conjugated to PVX via N-hydroxysuccini-
mide (NHS) chemistry targeting solvent-exposed lysine side
chains) and a His-tag at the N-terminus of HisTRAIL (purple
triangle). Multivalent display of HisTRAIL on the elongated PVX
particle allows efficient binding on death receptors DR4/5 (blue
trimers) to activate the caspase-dependent apoptosis in cancer
cells.
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avoiding disruption of native structures. (3) The conjugation
step is simple and achieved by mixing the Ni-NTA-displayed
nanostructure (here PVX) and His-tagged protein of interest
(here TRAIL) in buffer solutions, pH 7.4. (4) With the specific
binding of TRAIL to PVX via its designated N-terminal His-
tag, orientational control is provided, allowing for the bioactive
TRAIL at the C-terminus to be solvent-exposed upon NP
display, therefore mimicking its membrane-bound state when
in contact with surface-overexpressed DR4/5 receptors on
cancer cells.18,38 For confirming and characterizing the
therapeutic conjugate, size exclusion chromatography (SEC),
gel electrophoresis, transmission electron microscopy (TEM),
and quantitative Western blots (WB) were carried out. The
treatment efficacies of the therapeutic NPs were evaluated in
vitro in a panel of triple-negative breast cancer (TNBC) cell
lines, an aggressive breast cancer subtype whose treatment
options are limited in chemotherapies. Finally, the in vivo
evaluation was assessed to investigate whether TRAIL-loaded
PVX outperforms TRAIL alone in an athymic nude mouse
model bearing MDA-MB-231 TNBC tumors.
RESULTS
Preparation and Characterization of TRAIL-Loaded
PVX Nanoparticles. We have developed a protocol to
construct the plant viral NP-therapeutic protein complex
utilizing the coordination bond between the His-tagged
protein and the Ni-NTA chelate conjugated on PVX surface.
The scheme and detailed conjugation steps are described in
Supporting Information (Figures S1 and S2). Briefly, PVX was
first conjugated at its solvent-exposed lysine residues to display
nitrilotriacetic acid (PVX-NTA) using our established Cu(I)-
catalyzed azide−alkyne cycloaddition (CuCAAC) reaction
(“click” chemistry) protocol.28 Free reagents after the reaction
such as Cu ions and EDTA were removed by dialysis.
Subsequently, Ni2+ ions were introduced to PVX-NTA
suspension via dialysis in PBS containing 1 mM Ni2+ to
obtain PVX displaying Ni-NTA, hereafter PVX-Ni. The
presence of Ni-NTA conjugated on the viral NP was
qualitatively confirmed by adding 1,4-dithiothreitol (DTT)
100 mM final concentration; the reducing reagent converted
the solution from transparent into yellow, brownish color,
indicating the reduction of Ni2+ ions (Figure S2).
The therapeutic protein, hereafter denoted as HisTRAIL,
contains the amino acid (aa) 114−281 sequence of human
TRAIL, the region responsible for TRAIL bioactivity,36 a
designated N-terminal His-tag, and a thrombin cleavage
sequence allowing for removal of the His-tag if desired (Figure
S3A). HisTRAIL was expressed in ClearColi BL21(DE)3 and
purified using metal affinity chromatography under native
condition. The purified protein was characterized by gel
electrophoresis and WB (Figure S3B). It should be noted that
in recombinant TRAIL expression, dimers formed via
intermolecular disulfide bridge between Cys 230 typically
coexist with TRAIL monomers, while unpaired Cys 230 is
Figure 2. (A−C) Characterization of PVX-HisTRAIL-Cy5. (A) As-prepared PVX-Ni suspension (transparent), PVX-HisTRAIL-Cy5
suspension (blue), and TRAIL-Cy5 solution (blue). (B) SEC profiles of the corresponding PVX-based NP preparations. The inset shows co-
elution of HisTRAIL-Cy5 (absorbance 647 nm) with PVX (absorbance 260 nm, 280 nm). (C) Agarose gel electrophoresis of (1) PVX-Ni,
(2) PVX-HisTRAIL-Cy5, and (3) HisTRAIL-Cy5. The samples were visualized upon fluorescent excitation at 632 nm (red) and after
Coomassie blue (CB) staining under white light. (D) TEM images of negatively stained PVX-Ni (left) vs PVX-HisTRAIL-biotin (right), after
being treated with antibiotin antibodies conjugated with gold NPs. (E) Quantitative analysis of PVX-HisTRAIL by SDS-PAGE and Western
blot. In SDS-PAGE, (1) PVX-Ni, (2) HisTRAIL, and (3) PVX-HisTRAIL in the presence of DTT were run in 4−12% NuPAGE gel in 1 ×
MOPS running buffer. Separated PVX CP and HisTRAIL were indicated by the red and green arrows, respectively. To determine PVX and
HisTRAIL amounts by Western blot (stained with either anti-TRAIL or anti-PVX antibodies), the PVX-HisTRAIL conjugate was loaded at
either original concentration (4) or 10× dilution (4*) so that protein amounts lie within linear range of standard curves. For standard
curves, HisTRAIL was loaded at 0.25, 0.5, 1, 2.5, and 5 μg (5−9), and PVX was loaded at 0.1, 0.25, 0.5, 1 μg (5′−9’). Fluorescence intensities
were read from FluoroChem instrument.
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essential for bioactive TRAIL trimer formation and TRAIL/
receptor interactions.36 Therefore, purified HisTRAIL was
treated by 10 mM DTT for 1 h at room temperature and
followed by dialysis in PBS, pH 7.4, to remove excess DTT and
to favor HisTRAIL trimer formation; the latter was confirmed
by SDS-PAGE (Figure S3C). However, it should be noted that
while trimers were formed, a heterogeneous mixture of
multimeric HisTRAIL is expected, as typically seen in His-
tagged TRAIL.39,40 After obtaining PVX-Ni and HisTRAIL
separately, the two components were mixed in PBS at room
temperature to allow binding of HisTRAIL onto Ni-NTA on
PVX. The reaction mix was purified by ultracentrifugation to
remove unbound substances such as HisTRAIL and free Ni2+
ions if there are. The pellet was resuspended in PBS, pH 7.4
overnight to obtain the PVX-HisTRAIL suspension.
To visualize the presentation of HisTRAIL on PVX, we
utilized a Cy5-labeled HisTRAIL, referred as HisTRAIL-Cy5
(Figure S4); the resulting conjugate is referred to as PVX-
HisTRAIL-Cy5. After purification, the obtained conjugate
suspension exhibits a blue color derived from the present of
Cy5 (Figure 2A). SEC was conducted to confirm the intact
filamentous structure in PVX-Ni as well as PVX-HisTRAIL-
Cy5 after complexation and purification (Figure 2B). The
PVX-based nanostructures eluted from the Superose-6 column
at 14.5 mL, thus matching the elution profile of native PVX
(Figure S5; it should be noted that the molecular weights of
the PVX-based macromolecules are too large to resolve
differences between native and modified PVX particles using
this method). PVX-HisTRAIL-Cy5 absorbed light at 647 nm
at the elution peak of the particle (Figure 2B inset), indicating
the attachment of HisTRAIL-Cy5. Free HisTRAIL-Cy5 eluted
at 25−39 mL; for the PVX-HisTRAIL-Cy5 samples, no peaks
were detectable at this elution volume, indicating a purified
PVX-HisTRAIL preparation without presence of free His-
TRAIL-Cy5. Noteworthy, fluorescently labeled HisTRAIL-
Cy5 was prepared at a 1:1 (HisTRAIL:Cy5) molar ratio: As a
result, only 1 in every 4−5 HisTRAIL molecules were labeled
(Figure S4). The corresponding absorbance in the SEC profile
of PVX-HisTRAIL-Cy5 should only be considered as an
indicator of HisTRAIL binding on PVX-Ni. The absorbance
ratios of 260/280 nm were determined as 1.22 and 1.19 for
PVX-Ni and PVX- HisTRAIL-Cy5, respectively. The shift
toward the 280 nm absorbance (the 280 nm peak is indicative
of proteins, while 260 nm is a measure for RNA contents),
resulting in a decreased ratio for the PVX-HisTRAIL-Cy5
formulation, is another indicator of HisTRAIL-Cy5 loading.
Native gel electrophoresis (Figure 2C) was in agreement
with SEC, also indicating successful complexation of
HisTRAIL-Cy5 with PVX: Free HisTRAIL-Cy5 shows
mobility toward the anode, while PVX particle being a large
macromolecule does show a small degree of migration toward
the anode, but the majority of the samples remain in the
pockets of the gel. Co-localization of the fluorescent
HisTRAIL-Cy5, detected either by excitation at 632 nm
(red) light source or after Coomassie Blue (CB) staining and
visualization under white light, with PVX, detected after CB
staining under white light, is indicative of successful
HisTRAIL-Cy5-to-PVX loading. Again, free HisTRAIL-Cy5
was not apparent in this method.
Lastly, to confirm the structural integrity of TRAIL-
displaying PVX filaments, we made use of an immunogold-
labeling protocol: Similar to PVX-HisTRAIL-Cy5 preparation,
HisTRAIL was first biotinylated using biotin N-hydroxysucci-
nimide ester to provide a tag for immune staining (Figure S6).
PVX-HisTRAIL-biotin prepared by the described method was
loaded onto the TEM grid and fixed by 2.5% (v/v)
glutaraldehyde in 10 min. Bound HisTRAIL was detected
indirectly via the labeled biotin recognized by antibiotin
antibodies conjugated on 10 nm gold NPs. PVX-Ni was also
prepared using the same method as a control. The typical
filamentous structures imaged by TEM confirm structural
integrity for both, PVX-Ni and PVX-HisTRAIL-biotin samples
(Figure 2D). PVX-bound gold NPs were observed in the case
of PVX-HisTRAIL-biotin, demonstrating the multivalent
display of HisTRAIL on the PVX nanoplatform technology
(Figure 2D). It should be noted that due to the low labeling
degree of biotin (i.e., based on Cy5-labeling experiments, we
expect only a fraction of the HisTRAIL proteins to be labeled
with biotin), the amount of bound gold NPs does not provide
quantitative insights into the degree of labeling of PVX with
HisTRAIL.
The combination of methods utilizing Cy5- and biotin-
tagged TRAIL described above provides confidence in the
HisTRAIL conjugation and display method. Next, we
developed the therapeutic PVX-HisTRAIL conjugate (free of
fluorescent or biotin tags). After ultracentrifugal purification,
FPLC was conducted to ensure no free HisTRAIL in the PVX-
HisTRAIL suspension (Figure S7). Decrease in the 260/280
ratio is a sign of HisTRAIL bound to PVX. Various conditions
including buffers, PVX-Ni:HisTRAIL ratios, and reaction time
were optimized to achieve the highest yield of HisTRAIL on
PVX. Validation of complexation of the nonchemically
modified HisTRAIL to PVX was confirmed and quantified
by SDS-PAGE and WB (Figure 2E). PVX-Ni, His-TRAIL, and
PVX-HisTRAIL were separated on a 4−12% NuPAGE gel.
DTT was added to the sample mixtures to reduce nickel and
possible disulfide bonds and to separate bound HisTRAIL
from PVX CP. As a result, the corresponding individual bands
of the PVX CP (25 kDa) and HisTRAIL (22 kDa) were
observed after CB staining. Analysis of SDS-PAGE data using
band analysis tool and ImageJ software indicated a 32% weight
ratio of HisTRAIL to PVX CP. These data were further
validated by WB using rabbit anti-PVX and rabbit anti-TRAIL
primary antibodies, respectively, followed by staining with anti-
rabbit secondary antibodies conjugated with IRDye 800 CW
(774/789 nm). Data were in good agreement with SDS-PAGE
and indicated 2.45 μg HisTRAIL per 7.93 μg PVX CP, that is,
a protein weight ratio of 30.8%.
Using the known molecular weights of HisTRAIL (22 kDa)
and a PVX particle (36 × 105 kDa), ∼490 HisTRAIL
molecules were attached on a PVX particle (1270 CP units),
which equals ∼38% PVX CPs conjugated with a HisTRAIL
molecule. Considering 900 molecules per particle were added
into the mixture, the yield of the conjugation was >50%,
attesting to the effectiveness of the noncovalent display
strategy.
In Vitro Cytotoxicity Assays of PVX-HisTRAIL vs
HisTRAIL. We then set out to evaluate the anticancer efficacy
of the PVX-HisTRAIL therapeutic NP in parallel with
HisTRAIL, determined by MTT cytotoxicity assay. Herein, a
panel of TNBC cell lines, MDA-MB-231, HCC-38, and BT-
549, was used. Increasing concentrations of HisTRAIL or the
PVX-HisTRAIL conjugate at the corresponding HisTRAIL
concentrations were incubated with cells for 12 h to trigger
apoptosis. A representative data set of the concentration-
dependent effect of HisTRAIL vs PVX-HisTRAIL on MDA-
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MB-231 cell viability is shown in Figure 3A. Both HisTRAIL
and PVX-HisTRAIL exhibit cytotoxic bioactivity with PVX-
HisTRAIL outperforming free HisTRAIL. The IC50 value for
HisTRAIL on the PVX conjugate was determined at 26.7 ng
mL−1, which is 3.25-fold lower than the IC50 value for
HisTRAIL (86.6 ng mL−1). PVX-Ni did not exhibit cell
toxicity at the highest corresponding concentration in PVX-
HisTRAIL, confirming the biocompatibility of the delivery
platform. An even more profound effect was observed in other
TNBC cell lines (Table 1), with 9.9-fold and 9.3-fold lower in
IC50 values for PVX-HisTRAIL vs free HisTRAIL using HCC-
38 and BT-549 cell lines, respectively. Neither PVX-HisTRAIL
nor HisTRAIL induced apoptosis in SK-BR-3, the HER-2
amplified breast cancer cell line (Figure S8). These data are
consistent with previous reports that indicate effectiveness of
TRAIL therapy in TNBC, but not HER-2 positive breast
cancer.41,42 Given that TNBC is an aggressive, life-threatening
breast cancer subtype, whose available treatment is limited to
chemotherapy, this “PVX-bound” TRAIL concept might be a
promising approach for TRAIL-based therapy for future
TNBC treatment.
TRAIL-DR4/5 receptor binding activates caspase-depend-
ent apoptosis. Specifically, TRAIL-DR4/5 receptor binding
induces receptor oligomerization, followed by the recruitment
of FAS-associated protein with death domain (FADD) and
pro-caspase-8 to form a functional death-inducing signaling
complex (DISC) at the plasma membrane. Subsequently,
caspase-8 is activated and released into the cytosol, where it
cleaves and activates caspase-3 or caspase-7 to execute the
apoptosis in cancer cells (Figure 1).5 Therefore, we
determined differences in levels of caspase-8 and caspase-3/7
activated after 3 h treated by HisTRAIL or PVX-HisTRAIL in
the MDA-MB-231 model (Figure 3B). At a dose of 20 ng
mL−1 HisTRAIL, the level of caspase-8 in PVX-HisTRAIL
increased about 2-fold compared to the PBS control, while free
His-TRAIL protein only increased caspase-8 levels by 1.38-fold
compared to PBS. The resulting caspase-3/7 showed a similar
trend with a 2.9-fold increase for PVX-HisTRAIL and a 1.5-
fold for His-TRAIL vs PBS controls. These data are consistent
with results from cell viability assays, and data indicate that
surface-bound HisTRAIL displayed and delivered by PVX is
more effective in that it activates caspases leading to apoptosis
of TNBC cells.
In Vivo Treatment of MDA-MB-231 Tumors in the
Athymic Nude Mouse Models. Based on the promising
performance of PVX-HisTRAIL in vitro, we continued
investigating the tumor-inhibiting effects in an athymic nude
mouse model bearing an MDA-MB-231 tumor. The MDA-
MB-231 model was chosen because this cell line showed the
highest sensitivity toward the PVX-HisTRAIL treatment
(Table 1). While we envision systemic administration for
clinical applications, we started here by evaluating intratumoral
treatments to focus on the question as to whether PVX-
delivered HisTRAIL would outperform free HisTRAIL. The
intratumoral treatment allows to precisely control and match
the dosing and thus eliminates confounding factors from
varying biodistribution. Clinically, TRAIL is administrated
intravenously at doses of 10 mg kg−1. Assuming that 1−5% of
the injected dose (2.5−12.5 μg) reaches the tumor site,43,44 we
chose a dose of 5 μg HisTRAIL per tumor for intratumoral
injections. PVX-HisTRAIL or HisTRAIL was injected intra-
tumorally every 2 days. PBS and PVX-Ni, at the corresponding
particle amount injected for PVX-HisTRAIL (∼12−15 μg
particle per injection), were used as controls. Changes in
tumor volume during treatment and distribution of individual
tumor volume in each group are shown in Figures 4A,B,
respectively. Both HisTRAIL and PVX-HisTRAIL demon-
strate inhibiting effects with PVX-HisTRAIL outperforming
free HisTRAIL. The PVX-Ni carrier has no efficacy compared
to the PBS control group. At day 30 post-first treatment,
average relative tumor volume increased by 5.65-fold and 5.09-
fold for PVX-Ni and PBS groups, respectively. In contrast,
tumor volumes for the free HisTRAIL-treated group increased
by 2.53-fold, while there was essentially no increase in tumor
volume for the group treated with PVX-HisTRAIL (increase
was 1.09-fold vs starting volume; Figure 4A). Statistically
significant difference between PVX-HisTRAIL and the controls
(PBS and PVX-Ni) was apparent (p < 0.05 based on one-way
ANOVA test determined by GraphPad Prism; Figure 4B).
Even though there was no significant difference between PVX-
HisTRAIL and HisTRAIL, we could observe a clear trend
indicating more effective inhibition from the conjugate NP
Figure 3. (A) Cell viability assays of HisTRAIL vs PVX-HisTRAIL
determined using the MDA-MB-231 TNBC cell line model. (B)
Levels of activated caspase-8 and caspase-3/7 after 3 h treatment
by HisTRAIL or PVX-HisTRAIL (20 ng mL−1). Data were
expressed as means ± SD. Error bars shorter than the marker
sizes were not shown by GraphPad Prism software. Statistical
analysis was determined based on one-way ANOVA test calculated
by GraphPad Prism, * p < 0.05, *** p < 0.001, **** p < 0.0001.
Table 1. IC50 Values (ng mL
−1) of HisTRAIL vs PVX-
HisTRAIL in Various TNBC Models, Determined by
GraphPad Prism Software
MDA-MB-231 HCC-38 BT-549
HisTRAIL 86.8 367.2 543.0
PVX-HisTRAIL 26.7 36.8 58.0
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over HisTRAIL alone; four among six mice treated by PVX-
HisTRAIL showed reduced tumor volumes since the first
treatment, while all the mice treated by HisTRAIL showed
increased tumor volumes (Figures 4A,B). Representative
images of exercised tumors from each group are shown in
Figure 4C, in which the smallest is dissected from a mouse
treated by PVX-HisTRAIL at the end of treatment. Even
though not as effective as the conjugate formulate, HisTRAIL
also showed effective inhibition resulting in a smaller size
compared to the controls (Figure 4C).
The potential toxicity of the in vivo treatment was accessed
by monitoring changes in body weights of mice (Figure S9).
No changes in body weight were observed comparing the
various treatment groups, therefore indicating that the
treatment was well tolerated. While nickel can be toxic, here
the ions were used at low concentrations at 1−1.5 ppm. Based
on previous reports, this is in the low toxicity range.45
However, the localized administration also reduces systemic
exposure and likely mitigates Ni-induced toxicities.
Together, our data indicate that the PVX-delivered TRAIL
outperforms free TRAIL in a mouse model of TNBC; PVX-
delivered and displayed TRAIL shows high efficacy and as such
may be a promising candidate for further clinical development.
DISCUSSION
Nanotechnology delivery systems hold potential to enhance
efficacy of TRAIL cancer therapy. For example, soluble TRAIL
was used in combination with doxorubicin, a chemo-drug
acting as a TRAIL sensitizer that upregulates TRAIL receptors
DR4 and DR5.46 The dual-therapy resulted in a synergetic
effect achieving better tumor control compared to either
monotherapy. Recently, polymeric NPs were used as a
mechano-amplifiers to enhance the TRAIL-apoptotic effects.47
Furthermore, NPs have been developed as a carrier system to
deliver TRAIL and mimic the membrane-bound state of the
therapeutic protein to enhance the biostability and its efficacy
in vivo.12 Liposomes are probably the most exploited systems
in cancer nanotechnology, and liposomal formulations of
TRAIL have been reported. In one application, a TRAIL
derivative with engineered N-terminal cysteine residue was first
conjugated to a maleimide-functionalized lipid molecule that
was then incorporated into a PEGylated liposome, resulting in
a 90 nm vesicle displaying up to 60 TRAIL molecules (∼0.3%
mol of overall lipid molecules).18 Also noncovalent mod-
ification making use of the His-tag-Ni-NTA interactions was
demonstrated: His-tagged TRAIL was tethered onto Ni-NTA-
modified lipidic membranes of large, unilamellar vesicle
(LUV); up to 137 TRAIL molecules per 150 nm LUV were
presented.48 Furthermore, in an effort to mimic the cytotoxic
activity of natural killer cells, liposomes displaying TRAIL were
further decorated with E-selectin adhesion receptor to enable
the immobilization of TRAIL-NP onto leukocytes for detecting
and killing circulating colon and prostate cancer cells.49 In
addition to the described chemical display methods, genetic
engineering principles have been applied to fuse TRAIL into
the heavy chain of human ferritin, an intracellular protein that
can from a spherical nanocage from 24 subunits.50 Predicted
from the three-fold axis of symmetry characteristic of the
protein-based nanocage, eight TRAIL molecules in the trimeric
form can be displayed. The majority of TRAIL display
platform technologies explored are spherical NPs. However,
this may be not be optimal; a high aspect ratio filament is
expected to display the therapeutic protein more efficiently to
allow for multivalent interactions with the cell membrane. To
this end, one example exploring single-walled CNTs (SWNT,
1 × 600 nm) for TRAIL delivery has been reported.24 Here,
TRAIL was chemically conjugated with an NHS-handle
derived from 1-pyrenebutanoic acid N-hydroxysuccinimide
ester; the aromatic part noncovalently attached on SWNT via
π−π interactions. SWCNs with a median length of 600 nm are
able to display 26 molecules per particle, utilizing 80%
available space. These TRAIL delivery systems demonstrated
a 10−25-fold increase in efficacy in a wide variety of cell lines,
including leukemic, lymphoma, non-small cell lung cancer, or
hepatocarcinomas in vitro.18,24,48 Nevertheless, only a few NPs
displaying TRAIL were evaluated in vivo: TRAIL/liposome
systems have been shown to increase their pharmacodynamic
profiles and inhibit tumor growth by 65% via i.p. injection
every 2 days in the COLO205 human colorectal carcinoma
cells xenograft model.51 Ferritin-displayed trimeric TRAIL well
Figure 4. (A, B) Treatment of MDA-MB-231 xenografts in an
athymic nude mouse model. 6-week-old female NCR nu/nu mice
were injected subcutaneously into the right flank with 2 × 106
cells; treatment began when tumor volume reached 100−150 mm3,
approximately 2 weeks after tumor cell inoculation. Mice were
assigned randomly to each group: PVX-HisTRAIL: n = 6,
HisTRAIL: n = 5, PVX-Ni: n = 4, and PBS: n = 4. PVX-HisTRAIL
or HisTRAIL was injected intratumorally at the dose of 5 μg
HisTRAIL protein/injection every other day. Twenty μL PBS or
corresponding particle amount of PVX-Ni were injected as
controls. Tumor volume was normalized to the volume at the
initial day. Data were expressed as means ± SD (A) Tumor growth
curve during treatment. (B) Tumor volume distribution in each
group during treatment. (C) Representative of isolated tumor
tissues after treatment. Statistical analysis was determined based
on one-way ANOVA test calculated by GraphPad Prism, * p <
0.05, ** p < 0.01, *** p < 0.001.
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suppressed tumor growth, resulting in a 80.5% smaller tumor
volume compared to buffer-treated ones in the HepG2 human
hepatocellular carcinoma model.50 To date, there are no in vivo
studies for elongated nanostructures.13,52,53
The reported PVX-based nanostructure displaying TRAIL
offers advantages over previously explored systems: Data
indicate that high aspect ratio materials are more beneficial for
tumor drug delivery compared to spherical nanomaterials. To
date, only one such system has been described in the context of
TRAIL delivery, that is, using SWCNs. However, drawbacks
are the biosafety profiles of carbon-based materials and their
long residence time in the body (months).52 The proteina-
ceous PVX platform offers a higher degree of biosafety,
because the particles are readily biodegradable and cleared
from tissues within days.54
A further attributes of the PVX-TRAIL system are the easy
molecular farming to produce batches of filamentous particles
with a high degree of monodispersity and simple TRAIL
loading procedures that do not require chemical alteration of
the therapeutic protein TRAIL, ensuring its native structure for
bioactivity as well as providing orientational control by
coupling via its N-terminus. With PVX, we achieved TRAIL
loading to PVX with up to 490 TRAIL per PVX. This is the
same loading efficiency of our previous work for PVX
displaying fluorescent proteins30 and higher in loading capacity
compared to other systems.24,48 Considering the curvature
differences in sphere vs rod when in contact with cancer cells,
we hypothesize that our system would have enhanced cross-
linking ability with receptors and thus effectively induce high
levels of activated caspases signaling apoptosis. While
HisTRAIL heterogeneity (monomers vs multimers) could be
a concern, recent work indicates that multivalent presentation
of surface-bound TRAIL, even in its monomeric form,
efficiently induced clustering of death receptors leading to
apoptosis.24 In addition, multimerization was also enhanced for
His-TRAIL bound on NP carriers.54 In either scenarios,
enhances in in vitro and in vivo efficacies were both observed;
this could also be the case in our system, as a NTA group for
TRAIL binding was linked to PVX by a flexible PEG linker,
and this could favor the orientation of the therapeutic
protein.24,40 Our therapeutic system has shown a 10-fold
increase in treatment efficacy vs free drugs in a panel of TNBC
cell lines in vitro; this is comparable with other described
systems.18,24,48 Furthermore, we demonstrate the use of
elongated delivery system in the in vivo animal model bearing
MDA-MB-231 TNBC cell lines; PVX-bound TRAIL, when
intratumorally injected at the same dose, outperforms free
TRAIL in delaying growth of tumor volumes. This study is a
step toward bringing the TRAIL-based therapy, using
elongated NPs for presenting and delivering, toward transla-
tional evaluations. A future direction would be developing
genetic fusion techniques to incorporate TRAIL into PVX.
This would streamline manufacturing (avoiding post-harvest
modifications) and mitigate potential toxicity from the Ni used
for complexation of His-tagged TRAIL.
CONCLUSIONS
In conclusion, we demonstrate the use of PVX, a naturally
occurring nanoplatform with a flexuous filamentous structure
for TRAIL presentation and delivery, mimicking bioactive
membrane-bound TRAIL. When tested in a panel of TNBC
cell lines, PVX-HisTRAIL shows 3−10-fold enhanced cell-
killing effects to HisTRAIL alone in vitro. The conjugate also
effectively inhibited tumor growth in an athymic nude mouse
model of TNBC when injected intratumorally. In this study,
we focused on intratumoral treatment to dissect the differences
of efficacy comparing free vs PVX-displayed TRAIL given at
the same dosage. In addition, not only limited in
monotherapies, two-pronged therapeutic strategies could be
also developed, for example, PVX could display TRAIL and/or
additional targeting ligands while loading doxorubicin within
the grooves27 for synergetic effects in killing cancer, especially
in drug-resistant cell lines. Overall, this work not only
highlights the potentials of filamentous PVX for TRAIL-
based therapy but also provides valuable design guidelines for
developing therapeutic NPs, especially ones with high aspect
ratios, for clinical applications.
EXPERIMENTAL SECTION
Preparation of PVX Displaying Nickel-Coordinated Nitrilo-
triacetic Acid (PVX-Ni). PVX was propagated in Nicotiana
benthamiana plants and purified according to our established
protocol.28 About 20 mg of PVX particles were obtained from 100
g infected leaves. We developed a conjugation method to display Ni-
NTA as described in Figure S1. Briefly, PVX was first modified to
display azido groups (PVX-N3), followed by the Cu(I)-catalyzed
azide−alkyne cycloaddition (CuCAAC, “click” chemistry) reaction to
introduce the nitrilotriacetic (NTA) group. PVX displaying NTA
(PVX-NTA) was dialyzed against PBS, pH 7.4 containing 1 mM Ni2+
overnight at room temperature to obtain PVX displaying Ni-NTA
(PVX-Ni). The concentrations of PVX and its derivatives (PVX-N3,
PVX-NTA, PVX-Ni) were determined from the absorbance at 260
nm, read on a Nanodrop 2000 UV−vis spectrometer (Thermo
Fisher), and calculated using the Beer−Lambert law and PVX-specific
extinction coefficient (2.97 mL mg−1 cm−1 at 260 nm). To confirm
the presence of Ni2+ in the PVX-Ni formulation, PVX-Ni (2 mg
mL−1) was treated with DTT (Gold Biotechnology) at a 100 mM
final concentration; presence of Ni2+ is indicated by the solution
turning into a yellow-brownish color, which is indicative of the
reduction of Ni2+ ions (Figure S2).
Plasmid Construction, Protein Expression, and Purification
of HisTRAIL. A gene encoding the C-terminal extracellular region (aa
114−281) of TRAIL, flanked with NdeI and SacI restriction enzyme
sites at the 5′ and 3′ ends, respectively, was synthesized by Integrated
DNA Technologies (IDT). The gene fragment was excised by double
digestion using the enzymes NdeI and SacI (New England Biolabs,
NEB) and inserted into pET-28a(+) vector (a kind gift from Dr.
Ljerka Kunst, the University of British Columbia) at the
corresponding sites to yield pET-28a(+)/HisTRAIL, which was
subsequently transformed into Clear Coli BL21DE3 (Lucigen) for
expression. The expressed protein has an N-terminal His-tag, followed
by a thrombin cleavage sequence allowing for removal of the His-tag if
desired and a C-terminal bioactive human TRAIL (aa 114−281),
denoted as HisTRAIL (Figure S3A). Clear Coli BL21DE3 were
inoculated in TB culture for TRAIL expression, followed by the
purification using metal-affinity chromatography. Purified HisTRAIL
was confirmed by denaturing gel electrophoresis (SDS-PAGE) and
Western blot analysis (Figure S3B). Details of TRAIL expression,
purification, and characterization are described in Supporting
Information. The protein concentration was measured using a
Nanodrop 2000 UV−vis spectrometer. The extinction coefficient of
HisTRAIL was calculated as 27,390 M−1 cm−1 at 280 nm, using the
ProtParam tool (https://web.expasy.org/protparam/) based on the
number of tryptophan, tyrosine, and cysteine.
Size Exclusion Chromatography (SEC). The particles (PVX-Ni
or PVX-HisTRAIL-Cy5) or the protein (HisTRAIL-Cy5) in PBS, pH
7.4 were analyzed by SEC using a Superose-6 column on the ÄKTA
Explorer chromatography system (GE Healthcare). The flow rate was
set at 0.5 mL min−1. For detection of fluorescent molecules or
macromolecules, the absorbances at 260 nm (RNA), 280 nm
(protein), and 647 nm (Cy5) were recorded.
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Agarose Gel Electrophoresis. A 0.8% (w/v) agarose gel in TBE
buffer was prepared for gel electrophoresis. Samples (5 μg PVX-Ni or
PVX-HisTRAIL-Cy5 and 1 μg HisTRAIL-Cy5) were loaded and run
at 100 V for 40 min in TBE buffer. Gels were imaged using a
FluorChem R system instrument (ProteinSimple) upon excitation at
632 nm (red) for detection of the fluorescently labeled protein or
particle. Gels were then stained with CB and imaged under white light
using a FluorChem R system instrument.
Transmission Electron Microscopy (TEM) and Immunogold
Staining. TEM was used to confirm the filamentous structure of
PVX-HisTRAIL-biotin. In addition, immunostaining was performed
to further confirm that indeed biotinylated HisTRAIL was present on
PVX (PVX-HisTRAIL-biotin). PVX-HisTRAIL-biotin (0.1 mg mL−1)
and PVX-Ni (0.1 mg mL−1), the latter served as the negative control,
were loaded onto carbon-coated copper grids, followed by fixation in
2.5% (v/v) glutaraldehyde solution for 10 min at room temperature.
The grids were then washed with PBS, pH 7.4 and then blocked using
1% (w/v) bovine serum albumin (BSA) in PBS, pH 7.4 containing
0.1% (v/v) Tween 20 for 30 min. Samples were equilibrated with
0.1% (w/v) BSA for 5 min and then stained with 10 nm gold NPs
conjugated with antibiotin antibodies (AURION) diluted 5 times in
PBS, pH 7.4. All samples were negative-stained using 2% (w/v) uranyl
acetate for 1 min prior to TEM imaging. TEM imaging was conducted
using an FEI Tecnai F30 transmission electron microscope operated
at 300 kV.
Denaturing Gel Electrophoresis, SDS-PAGE, and Fluores-
cent Western Blot (WB) for TRAIL Quantitative Analysis.
Denatured protein samples (5 μg) in the presence of reducing reagent
DTT were loaded on a 4−12% NuPAGE gel (Life Technologies) in 1
× MOPS running buffer. The electrophoresis was conducted at a
constant voltage (200 V) for 35 min. Protein bands were visualized
under white light after CB staining by FluoroChem R imaging
instrument. Band thickness analyses were analyzed by ImageJ 1.47d
(http://imagej.nih.gov/ij) to determine the weight ratio between
HisTRAIL and PVX CP.
For WB, PVX-HisTRAIL was loaded with 10 μL suspension at 1.0
mg mL−1 or 10× dilution under denaturing condition with DTT. This
concentration range was within the linear detection range of a
standard curve which was established using PVX and HisTRAIL at
defined and known concentrations. Protein concentrations were
determined by Bradford assay kit (Biorad). For the PVX standard
curve, 0.1, 0.25, 0.5, 1 μg particles were loaded. For HisTRAIL
standard curve, the protein was loaded at 0.25, 0.5, 1, 2.5, and 5 μg.
After separation of PVX-HisTRAIL and controls by SDS-PAGE, the
proteins were transferred onto a nitrocellulose membrane (Thermo
Scientific) using NuPAGE transfer buffer (Invitrogen). Blocking was
conducted in 0.1 M Tris-buffered saline (TBS, pH 7.6) containing 5%
(w/v) milk and 0.05% (v/v) Tween 20. PVX and HisTRAIL were
detected using a rabbit anti-PVX antibody (Pacific Immunology) and
a rabbit anti-TRAIL primary antibody (Biovision), followed by
detection from anti-rabbit secondary antibody conjugated with IRDye
800 CW (774/789 nm) (LICOR). The membrane was visualized
under infrared light; the fluorescence intensities were determined by
FluoroChem R imaging instrument.
Cell Culture. Triple-negative breast cancer (TNBC) MDA-MB-
231, HCC-38, and BT-549 cell lines as well as the HER-2 amplified
breast cancer, SK-BR-3 cell line were purchased from ATCC. MDA-
MB-231, HCC-38, BT-549, and SK-BR-3 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM), Roswell Park Memorial Institute
(RPMI) 1640 medium without or with insulin (0.023 IU/mL final
concentration), and McCoy’s 5A medium, respectively. All media
were supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/
streptomycin. All cells were maintained at 37 °C and 5% CO2.
MTT Cytotoxicity Assays. Cells (MDA-MB-231, HCC-38, BT-
549, and SK-BR-3) were seeded at 5000 cells per well in the
corresponding culture medium in 96-well plates 1 day prior to
treatment. The next day, cells were treated with HisTRAIL or PVX-
HisTRAIL at 1, 5, 10, 25, 50, 100, 250, 500 ng mL−1 normalized to
HisTRAIL for 12 h in medium at 37 °C and 5% CO2. Samples were
prepared in triplicate, and each assay was performed at least twice.
PVX-Ni was added at the particle concentration matching the highest
dose of PVX-HisTRAIL as a control to assess carrier toxicity (or lack
thereof). Following incubation, cells were washed with PBS, pH 7.4,
and fresh medium was replenished, and then 10 μL MTT reagent was
added as per manufacturer’s instructions. Absorbance was determined
using the Tecan infinite-M200 plate reader.
Determination of Levels of Activated Caspase-8 and
Caspase-3/7. MDA-MB-231 cells were seeded at 5000 cells per
well in a white-walled 96-well luminometer microplate 1 day prior to
treatment. The next day, medium was exchanged with DMEM
medium containing HisTRAIL or PVX-HisTRAIL (20 ng mL−1);
treatment was allowed to proceed for 3 h. Nontreated cells were used
as control. Samples were prepared in triplicate. Caspase-Glo 8 assay
kit and Caspase-Glo 3/7 assay kit (Promega) were used to determine
the level of activated caspases upon HisTRAIL or PVX-HisTRAIL
treatment. Briefly, the reagent causes cell lysis, followed by caspase
cleavage of the substrate and aminoluciferin which produces a
luminescent signal in the presence of luciferase and ATP from the kit.
Luminescence was read by the Tecan infinite-M200 plate reader to
determine the proportional activated level of caspase-8 and caspase-3/
7.
In Vivo Treatment Efficacy Using the MDA-MB-231 Model.
The animal study was carried under a Case Western Reserve
University IACUC-approved protocol. Female NCR nu/nu mice (6−
8 weeks old) were injected subcutaneously into the right flank with 2
× 106 cells suspended in 100 μL of media and Matrigel (Corning) at a
1:1 ratio. Treatment was started when tumor volume reached 100−
150 mm3. Mice were randomly assigned to groups including PBS- (n
= 4), PVX-Ni- (n = 4), HisTRAIL- (n = 5), and PVX-HisTRAIL-
treated groups (n = 6). Freshly prepared HisTRAIL or PVX-
HisTRAIL was injected intratumorally at a dose of 5 μL therapeutic
protein per injection. PBS and PVX-Ni, at the corresponding content
of particle in the conjugate, were used as controls. Tumors were
measured daily, and the volume was calculated using the formula v =
(l × w2)/2, where l is the length and w is the width of tumor. Mice
were also weighted to monitor potential side effects. All mice were
euthanized, and tumors were collected at the end of the study for
imaging. All results are expressed as means ± SD, calculated by
GraphPad Prism. Statistical comparisons were made using one-way
ANOVA. Differences between each group were considered significant
at P value <0.05.
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